Neervannan Seshadri, Chief Operating Officer of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), disposed of 11,324 shares of common stock across three separate transactions from March 17 to March 19, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
The combined proceeds from the sales totaled $772,443, with per-share prices ranging from $67.00 to $69.42. The filing breaks down the trades as follows: 3,125 shares were sold on March 17 at $69.42 per share; 3,610 shares were sold on March 18 at $68.71 per share; and 4,589 shares were sold on March 19 at $67.00 per share. As of the filing, the stock was trading at $66.75.
The Form 4 specifies that the shares sold were used to cover tax withholding obligations that arose from the vesting and settlement of Restricted Stock Units. The filing states these withholdings were mandated by the company.
Following the transactions, Seshadri directly holds 85,780 shares of Tarsus Pharmaceuticals common stock. The filing also notes that Seshadri’s daughter directly owns 475 shares.
Company performance and recent results
The company is valued at $2.85 billion and has posted a 34.7% return over the last year. Tarsus reported exceptional revenue growth of 147% over the same period. In its most recent reporting, Tarsus Pharmaceuticals disclosed net product sales of $151.7 million for the fourth quarter of 2025 and $451.4 million for the full year, results the company attributes to the performance of its flagship product, XDEMVY.
Despite the strong reported sales and revenue growth, the stock experienced a modest decline in aftermarket trading following the financial release, signaling a restrained market reaction even as earnings and revenue figures remained key points of focus for stakeholders.
Separately, InvestingPro analysis is referenced in the filing as suggesting that Tarsus is undervalued relative to its Fair Value.
What the filing shows
- Insider sales were executed over three days: March 17, March 18 and March 19, 2026.
- Total shares sold by the COO: 11,324, generating $772,443.
- Sale prices ranged from $67.00 to $69.42 per share; stock quoted at $66.75 at the time of reporting.
- Sales were made to satisfy tax withholding obligations tied to RSU vesting and were mandated by the company.
The disclosure provides a clear accounting of the transactions and the post-transaction holdings of the executive and a family member, while the company’s recent financials underline the scale of commercial traction for XDEMVY.